A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL STUDY TO EVALUATE THE ANALGESIC EFFECT OF AQUEOUS EXTRACT OF TERMINALIA CHEBULA, A PROPRIETARY CHROMIUM COMPLEX, AND THEIR COMBINATION IN SUBJECTS WITH JOINT DISCOMFORT

  • Chandrasekhar Nutalapati Senior Resident, Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad 500082
  • Uday Kumar Chiranjeevi Senior Resident, Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad 500082
  • Kishan P V Senior Resident, Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad 500082
  • Kiran Kishore K Senior Resident, Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad 500082
  • Usharani Pingali

Abstract

Objective: To evaluate the analgesic effect of an aqueous extract of Terminalia chebula (TCE), a proprietary chromium complex (PCC), and their
combination in subjects with joint discomfort.
Methods: A total of 100 patients with knee joint discomfort were randomized into five treatment groups - TCE 500 mg BID, TCE 500 mg BID+PCC
400 µg OD, PCC 400 µg OD alone, placebo, and TCE 250 mg BID, for 12 weeks in a double-blinded manner. Assessment of symptoms of knee joint pain
and discomfort was done by modified Western Ontario and McMaster Universities Arthritis Index (mWOMAC) and knee swelling index (KSI); visual
analog scale (VAS) was used for subjective assessment of pain, stiffness, and disability. Statistical analysis was done with GraphPad Prism 6.
Results: Absolute reduction in mWOMAC score in TCE 500 mg (19.82±8.35), TCE 500 mg+PCC 400 µg (13.10±5.69), PCC 400 µg (8.30±3.81), placebo
(2.45±3.07), and TCE 250 mg (10.47±4.43), respectively, at the end of 12 weeks as compared to the baseline values. Absolute reduction in KSI in
TCE 500 mg (28.95±16.82), TCE 500 mg+PCC 400 µg (19.14±9.50), PCC 400 µg (12.7±4.86), placebo (10.03±3.8), and TCE 250 mg (18.24±6.86),
respectively, at the end of 12 weeks as compared to the baseline values (p<0.001). Similar results were seen with VAS assessments for pain, stiffness,
and disability. All the treatments were well tolerated.
Conclusion: TCE and PCC reduce joint discomfort.
Keywords: Terminalia chebula extract, Proprietary chromium complex, Western Ontario and McMaster Universities Arthritis Index.

References

1. Gerwin N, Hops C, Lucke A. Intra-articular drug delivery in
osteoarthritis. Adv Drug Deliv Rev 2006;58(1):226-42.
2. Fransen M, Bridgett L, March L, Hoy D, Penserga E, Brooks P.
The epidemiology of osteoarthritis in Asia. Int J Rheum Dis
2011;14(2):113-21.
3. Mahajan A, Verma S, Tandon V. Osteoarthritis. J Assoc Physicians
India 2005;53:634-41.
4. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older
adults: A review of community burden and current use of primary
health care. Ann Rheum Dis 2001;60(2):91-7.
5. Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol
2006;47 Suppl 1:S60-6.
6. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa
and dyspeptic symptoms in arthritic patients during chronic nonsteroidal
anti-inflammatory drug use. Am J Gastroenterol 1987;82(11):1153-8.
7. Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain
Symptom Manage 2003;25 Suppl 2: S32-40.
8. Surya Prakash DV, Sree Satya N, Avanigadda S, Vangalapati M.
Pharmacological review on Terminalia chebula. Int J Res Pharm
Biomed Sci 2012;3(2):679-83.
9. Nair V, Singh S, Gupta YK. Anti-arthritic and disease modifying
activity of Terminalia chebula Retz. in experimental models. J Pharm
Pharmacol 2010;62(12):1801-6.
10. Reddy DB, Reddy TC, Jyotsna G, Sharan S, Priya N, Lakshmipathi V,
et al. Chebulagic acid, a COX-LOX dual inhibitor isolated from the
fruits of Terminalia chebula Retz. induces apoptosis in COLO-205 cell
268
Asian J Pharm Clin Res, Vol 9, Issue 3, 2016, 264-269
Nutalapati et al.
line. J Ethnopharmacol 2009;124(3):506-12.
11. Kumar CU, Pokuri VK, Pingali U. Evaluation of the analgesic activity
of standardized aqueous extract of Terminalia chebula in healthy human
participants using hot air pain model. J Clin Diagn Res 2015;9(5):01-04.
12. Pratibha N, Saxena VS, Amit A, D’Souza P, Bagchi M, Bagchi D. Antiinflammatory
activities
of Aller-7,
a novel polyherbal
formulation
for

allergic
rhinitis. Int J Tissue
React 2004;26(1-2):43-51.
13. Fleck A, Gupta RC, Goad JT, Lasher MA, Canerdy TD, Kalidindi SR.
Anti-arthritic efficacy and safety of crominex 3
(Trivalent chromium,
Phyllanthus emblica extract, and Shilajit) in moderately arthritic dogs.
J Vet Sci Anim Husbandry 2014;19(4):1-7.
+
14. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis.
Ann Rheum Dis 1957;16(4):494-502.
15. Available from: http://www.copcord.org/images/WOMAC.pdf.
16. Juang LJ, Sheu SJ. Chemical identification of the sources of commercial
Fructus Chebulae. Phytochem Anal 2005;16(4):246-51.
17. Seo JB, Jeong JY, Park JY, Jun EM, Lee SI, Choe SS, et al.
Anti-arthritic and analgesic effect of NDI10218, a standardized extract
of Terminalia chebula, on arthritis and pain model. Biomol Ther (Seoul)
2012;20(1):104-12.
18. Bag A, Bhattacharyya SK, Chattopadhyay RR. The development of
Terminalia chebula Retz. (Combretaceae) in clinical research. Asian
Pac J Trop Biomed 2013;3(3):244-52.
19. Muhammad S, Khan BA, Akhtar N, Mahmood T, Rasul A, Hussain I.
The morphology, extractions, chemical constituents and uses of
Terminalia chebula: A review. J Med Plants Res 2012;6(33):4772-5.
20. Reddy DB, Reddanna P. Chebulagic acid (CA) attenuates LPS-induced
inflammation by suppressing NF-kappaB and MAPK activation
in RAW 264.7 macrophages. Biochem Biophys Res Commun
2009;381(1):112-7.
21. Jagetia GC, Rao SK, Baliga MS, S Babu K. The evaluation of nitric
oxide scavenging activity of certain herbal formulations in vitro: A
preliminary study. Phytother Res 2004;18(7):561-5.
22. Sumantran VN, Kulkarni AA, Harsulkar A, Wele A, Koppikar SJ,
Chandwaskar R, et al. Hyaluronidase and collagenase inhibitory
activities of the herbal formulation Triphala guggulu. J Biosci
2007;32(4):755-61.
23. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid
arthritis: Mechanistic insights and approaches to prevention. Rheum
Dis Clin North Am 2010;36(2):385-404.
24. Sabina EP, Rasool M. Therapeutic efficacy of Indian ayurvedic herbal
formulation triphala on lipid peroxidation, antioxidant status and
inflammatory mediator TNF-α in adjuvant induced arthritic mice. Int J
Biol Chem 2007;1(3):149-55.
Statistics
487 Views | 632 Downloads
How to Cite
Nutalapati, C., U. K. Chiranjeevi, K. P V, K. K. K, and U. Pingali. “A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL STUDY TO EVALUATE THE ANALGESIC EFFECT OF AQUEOUS EXTRACT OF TERMINALIA CHEBULA, A PROPRIETARY CHROMIUM COMPLEX, AND THEIR COMBINATION IN SUBJECTS WITH JOINT DISCOMFORT”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 9, no. 3, May 2016, pp. 264-9, https://innovareacademics.in/journals/index.php/ajpcr/article/view/11217.
Section
Original Article(s)